Tolerogenic Programming Promotes Human Cytomegalovirus Permissiveness in Dendritic Cells
Rahmel-Stein K, Becker J, Lange B, Krajewski L, Eiz-Vesper B, Kalinke U
Tolerogenic dendritic cells offer a niche for human cytomegalovirus

Human cytomegalovirus (HCMV) is a major global health burden that causes lifelong infection in humans. It is the leading infectious cause of developmental disabilities in children and can be life-threatening to individuals with a weakened immune system, for example in transplant patients. Despite 70 years of research on HCMV, it is still not fully understood how the virus evades immune control. Researchers from TWINCORE, Centre for Experimental and Clinical Infection Research have now shown how the virus escapes immune surveillance. These findings have recently been published in the European Journal of Immunology.
Dendritic cells (DCs) are central regulators of immunity. They detect pathogens and coordinate the adaptive immune response by activating other immune cells, particularly T cells. DCs are important targets of HCMV, but the factors that determine their susceptibility to infection are not fully known. In a previous study, the researchers from the Institute for Experimental Infection Research at TWINCORE had identified a subset of monocyte-derived DCs (moDCs) that lack the surface markers CD1a and CD86, and have a tolerogenic gene expression profile. This particular cell subset supported viral gene expression more efficiently than other moDCs. To investigate whether a tolerogenic state itself increases susceptibility, the researchers generated tolerogenic DCs (tolDCs) and examined how readily they got infected.
"We used three previously established protocols to generate tolDCs by treating the cells with either vitamin D3 (VitD3), dexamethasone (Dexa), or their combination," says PhD student Katharina Rahmel-Stein, the first author of the publication.
Using these approaches, the researchers found that tolDCs generated with Dexa alone or combined with VitD3 resisted to maturation, while VitD3-treated cells remained more responsive to activating signals. "Our findings highlight that tolDCs are not a uniform cell population. They can differ considerably depending on the protocol used and the individual donor," says Jennifer Becker, former postdoc in the research team and now Scientific Coordinator at the Helmholtz Institute for Translational AngioCardioScience (HI-TAC).
The experiments confirmed that HCMV-exposed tolDCs were more susceptible to infection than conventional moDCs. Despite their higher susceptibility, HCMV-exposed tolDCs activated T cells poorly. They showed reduced surface levels of molecules that present viral components to T cells, along with lower levels of costimulatory markers required for T-cell activation. Consistent with this, HCMV-exposed tolDCs induced markedly less proliferation of both CD4+ and CD8+ T cells compared with conventional moDCs.
"What is particularly interesting is that although tolDCs seem to provide a favorable environment for HCMV infection, they are less effective at stimulating antiviral T-cell responses," says Katharina Rahmel-Stein.
"Together, these findings identify tolDCs as a permissive niche for HCMV and suggest that the virus may benefit from the reduced immune-stimulatory capacity of these cells," says Ulrich Kalinke, Executive Director of TWINCORE and head of the Institute for Experimental Infection Research.
The study shows how the functional state of immune cells affects both their vulnerability to HCMV and their ability to trigger antiviral immunity. Whether similar cell populations contribute to infection and immune evasion in humans remains to be investigated. Identifying which immune cells are particularly vulnerable to HCMV, and why, could pave the way for more targeted therapies.
Rahmel-Stein K, Becker J, Lange B, Krajewski L, Eiz-Vesper B, Kalinke U

Researchers investigate the impact on the immune system.

How bacteria develop resistance to antisense antibiotics - and how future therapies can be designed to reduce the risk of resistance

A team of researchers from Hamburg, Berlin, Göttingen and Hannover has provided evidence of possible cross-protection offered by an already authorised Zaire Ebola virus vaccine.